UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.           )

Filed by the Registrant 

Filed by a Party other than the Registrant 

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

ACORDA THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)

Title of each class of securities to which transaction applies:

 

 

(2)

Aggregate number of securities to which transaction applies:

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

(4)

Proposed maximum aggregate value of transaction:

 

 

(5)

Total fee paid:

 

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)

Amount Previously Paid:

 

 

(2)

Form, Schedule or Registration Statement No.:

 

 

(3)

Filing Party:

 

 

(4)

Date Filed:

 


 


Text of communication sent to certain Acorda Therapeutics, Inc. shareholders

 

 

Dear XX,

 

Acorda Therapeutics is holding a special stockholder meeting on July 31. The proposals up for vote at this meeting, an increase in authorized shares proposal and a reverse stock split proposal, are critical to our company’s future. Both ISS and Glass Lewis recommend that shareholders vote “for” these proposals.

 

Due to the high percentage of retail shareholders who own ACOR, it is very important that all institutional shareholders remember to vote so that we are able to establish a quorum for the meeting.

 

As far as we can tell, your fund has not yet voted, and we would be grateful if you would ensure that you do.

 

Please feel free to contact me if you have any questions.

 

Best regards,

 

 

 

 

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Acorda Therapeutics Charts.
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Acorda Therapeutics Charts.